** Shares of drug developer Actuate Therapeutics ACTU.O rise 7.2% to $10.6 premarket
** ACTU's experimental drug, elraglusib, in combination with chemotherapy met the main goal of statically significant improvement in overall survival in a mid stage trial, compared to chemotherapy alone
** The drug was being tested in first-line treatment of metastatic pancreatic ductal adenocarcinoma – a type of cancer that starts in the ducts of the pancreas and has spread to other parts of the body
** Co says the drug helped patients survive for a year
** Up to last close, ACTU stock up 24.25% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。